TRCT
BBIO icon

Tower Research Capital (TRC)’s BridgeBio Pharma BBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
14,349
+13,235
+1,188% +$959K 0.03% 515
2025
Q4 		$85.2K Sell
1,114
-6,424
-85% -$422K ﹤0.01% 2044
2025
Q3 		$392K Sell
7,538
-5,338
-41% -$260K 0.01% 1017
2025
Q2 		$556K Buy
12,876
+5,373
+72% +$195K 0.02% 892
2025
Q1 		$259K Sell
7,503
-13,275
-64% -$448K 0.01% 1222
2024
Q4 		$570K Buy
20,778
+18,679
+890% +$483K 0.01% 970
2024
Q3 		$53.4K Sell
2,099
-31,534
-94% -$828K ﹤0.01% 2686
2024
Q2 		$852K Buy
33,633
+32,328
+2,477% +$884K 0.01% 894
2024
Q1 		$40.4K Sell
1,305
-6,912
-84% -$235K ﹤0.01% 2421
2023
Q4 		$332K Buy
8,217
+6,231
+314% +$187K ﹤0.01% 1700
2023
Q3 		$52.4K Sell
1,986
-12,173
-86% -$345K ﹤0.01% 2514
2023
Q2 		$244K Buy
14,159
+9,771
+223% +$147K 0.01% 1417
2023
Q1 		$72K Sell
4,388
-2,096
-32% -$24.4K ﹤0.01% 2170
2022
Q4 		$50K Sell
6,484
-10,311
-61% -$98.7K ﹤0.01% 2346
2022
Q3 		$167K Sell
16,795
-16,018
-49% -$166K ﹤0.01% 2096
2022
Q2 		$298K Buy
32,813
+15,247
+87% +$128K 0.01% 1486
2022
Q1 		$179K Buy
17,566
+1,050
+6% +$10.8K ﹤0.01% 1812
2021
Q4 		$275K Buy
16,516
+4,684
+40% +$198K ﹤0.01% 1531
2021
Q3 		$554K Buy
11,832
+6,485
+121% +$348K 0.01% 913
2021
Q2 		$326K Sell
5,347
-2,232
-29% -$127K 0.01% 1526
2021
Q1 		$467K Buy
7,579
+5,105
+206% +$334K 0.01% 1294
2020
Q4 		$176K Sell
2,474
-897
-27% -$43.3K 0.01% 1819
2020
Q3 		$127K Sell
3,371
-20,405
-86% -$642K ﹤0.01% 2946
2020
Q2 		$775K Buy
+23,776
New +$724K 0.03% 685
2020
Q1 		– Sell
-1,097
Closed -$38K – 3047
2019
Q4 		$38K Buy
1,097
+634
+137% +$17.6K ﹤0.01% 1504
2019
Q3 		$10K Buy
+463
New +$12.8K ﹤0.01% 2913

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s BBIO Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its BridgeBio Pharma (BBIO) stake by 1,188% in Q1 2026, buying an estimated $959K and bringing the position to 14,349 shares worth $1.07M. The position accounts for 0.03% of the portfolio, ranked #515.

Tower Research Capital (TRC) first reported a position in BBIO in Q3 2019 and has held it in 26 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Tower Research Capital (TRC) held 14,349 shares of BridgeBio Pharma worth $1.07M as of Q1 2026.
  • Tower Research Capital (TRC) bought 13,235 BridgeBio Pharma shares in Q1 2026, an estimated $959K.
  • BridgeBio Pharma made up 0.03% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #515 holding.
  • Tower Research Capital (TRC) first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 26 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.